NewAmsterdam Pharma (NAMS) Competitors $18.57 -0.43 (-2.26%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$18.78 +0.21 (+1.13%) As of 02/21/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NAMS vs. RVMD, LEGN, BBIO, AXSM, BPMC, TLX, ELAN, LNTH, NUVL, and CYTKShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics NewAmsterdam Pharma (NASDAQ:NAMS) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership. Which has more risk & volatility, NAMS or RVMD? NewAmsterdam Pharma has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Is NAMS or RVMD more profitable? NewAmsterdam Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Revolution Medicines N/A -33.67%-30.08% Do insiders and institutionals hold more shares of NAMS or RVMD? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 8.0% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor NAMS or RVMD? In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 4 articles in the media. Revolution Medicines' average media sentiment score of 0.73 beat NewAmsterdam Pharma's score of 0.71 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, NAMS or RVMD? NewAmsterdam Pharma has higher revenue and earnings than Revolution Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$14.09M121.77-$176.94MN/AN/ARevolution Medicines$11.58M600.54-$436.37M-$3.59-11.52 Do analysts rate NAMS or RVMD? NewAmsterdam Pharma presently has a consensus target price of $41.60, indicating a potential upside of 124.02%. Revolution Medicines has a consensus target price of $66.25, indicating a potential upside of 60.26%. Given NewAmsterdam Pharma's higher probable upside, equities analysts plainly believe NewAmsterdam Pharma is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Does the MarketBeat Community believe in NAMS or RVMD? Revolution Medicines received 67 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 75.83% of users gave Revolution Medicines an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes24100.00% Underperform VotesNo VotesRevolution MedicinesOutperform Votes9175.83% Underperform Votes2924.17% SummaryRevolution Medicines beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.72B$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A5.7325.8218.54Price / Sales121.77312.55453.6679.35Price / CashN/A67.8344.0537.40Price / Book5.316.747.634.64Net Income-$176.94M$138.11M$3.18B$245.69M7 Day Performance-6.73%-2.54%-1.95%-2.67%1 Month Performance-20.54%-2.00%-0.23%-2.16%1 Year Performance-13.83%-5.04%16.69%12.90% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.2893 of 5 stars$18.57-2.3%$41.60+124.0%-13.9%$1.72B$14.09M0.004Upcoming EarningsRVMDRevolution Medicines4.5103 of 5 stars$40.67-1.6%$66.25+62.9%+41.7%$6.84B$11.58M-11.33250LEGNLegend Biotech2.594 of 5 stars$36.42+0.1%$79.50+118.3%-33.7%$6.65B$285.14M-38.341,800News CoveragePositive NewsGap UpBBIOBridgeBio Pharma4.7202 of 5 stars$34.90+10.6%$49.08+40.6%+7.9%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5266 of 5 stars$131.15-0.4%$147.13+12.2%+67.8%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines3.0033 of 5 stars$93.94-1.3%$123.83+31.8%+5.7%$5.97B$249.38M-44.52640Earnings ReportAnalyst UpgradeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.057 of 5 stars$11.26-3.4%$16.29+44.7%-31.9%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.5803 of 5 stars$79.94-2.5%$131.86+64.9%+37.9%$5.56B$1.30B13.30700Analyst RevisionNews CoveragePositive NewsNUVLNuvalent2.1318 of 5 stars$77.93-3.7%$112.36+44.2%-3.7%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.1875 of 5 stars$46.16+10.9%$82.00+77.6%-34.3%$5.45B$7.53M-8.58250News CoverageHigh Trading Volume Related Companies and Tools Related Companies Revolution Medicines Alternatives Legend Biotech Alternatives BridgeBio Pharma Alternatives Axsome Therapeutics Alternatives Blueprint Medicines Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Elanco Animal Health Alternatives Lantheus Alternatives Nuvalent Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NAMS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts